ZYN 001

Drug Profile

ZYN 001

Alternative Names: THC prodrug transdermal patch; ZYN001

Latest Information Update: 17 Mar 2016

Price : $50

At a glance

  • Originator Zynerba Pharmaceuticals
  • Class Antiemetics; Cannabinoids; Esters; Neuroprotectants; Non-opioid analgesics; Sugar acids
  • Mechanism of Action Cannabinoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer pain; Fibromyalgia; Neuropathic pain

Most Recent Events

  • 14 Mar 2016 Zynerba Pharmaceuticals plans a phase I trial for Fibromyalgia
  • 11 Nov 2015 Zynerba plans phase IIa trials for Fibromyalgia and Peripheral neuropathic pain
  • 01 Oct 2014 Preclinical trials in Cancer pain in USA (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top